NovoCure

Treatment of Brain Tumors Using Electric Fields

Health Tech & Life Sciences
Public on NASDAQ on Oct, 2015<br>
Follow

Company Overview

Snapshot

Founded in April 1999 by Prof. Yoram Palti, NovoCure is a public company with over 1,000 employees. The company has raised a total of $742 million across five funding rounds. In May 2024, NovoCure secured new debt financing.

Business overview

NovoCure is a commercial-stage oncology company focused on developing and commercializing its proprietary Tumor Treating Fields (TTFields) therapy for solid tumor cancers. This novel, non-invasive technology utilizes low-intensity, intermediate-frequency alternating electric fields to disrupt cancer cell division. The therapy is delivered via transducer arrays placed on the skin, connected to a portable electric field generator. NovoCure serves the healthcare and life sciences sectors, specifically targeting patients and providers in oncology with its medical treatment and therapeutic solutions.

Strategic signal

In September 2024, NovoCure announced it would present real-world data at ESMO 2024, demonstrating improved survival outcomes for newly diagnosed glioblastoma patients with increased use of its Tumor Treating Fields (TTFields) Therapy. This signals continued clinical validation and potential for broader adoption of its core technology, reinforcing its position in the oncology market and offering a positive outlook for investors regarding patient outcomes and market penetration.

Log in to access full profile ›

Company Intelligence Q&A

What was a significant recent leadership change at NovoCure?
In September 2024, NovoCure announced a planned CEO transition, with Asaf Danziger retiring and CFO Ashley Cordova named as his successor.
What recent financial results did NovoCure report?
In October 2024, NovoCure reported its Third Quarter 2024 financial results, noting a Q3 loss but topping revenue estimates.
What is the status of NovoCure's Optune Lua device in Japan?
In September 2025, NovoCure's Optune Lua® device received approval in Japan for the treatment of unresectable advanced/recurrent non-small cell lung cancer (NSCLC).
What clinical trial results is NovoCure planning to present in 2025?
In September 2025, NovoCure is scheduled to present final results from the pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for brain metastases from non-small cell lung cancer at the 2025 ASTRO Annual Meeting.
When did NovoCure go public?
NovoCure went public on NASDAQ in October 2015, raising $165 million with a valuation of $1.8 billion.
Log in to access full profile ›

External links